Company intelligence / Profile preview

Neuronasal

New York, New York, United Statesneuronasal.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Neuronasal has completed a pilot study demonstrating nose-to-brain delivery of N-acetylcysteine (NAC) and has received IND clearance for Phase 1 trials. NAC shows potential in treating mTBI by reducing oxidative stress and inflammation.

Therapeutic areas: Neurology
Modalities: Small molecules (e.g., N-acetylcysteine)
Industry: Biotech

Drug pipeline

1 asset

n-acetylcysteine

Phase 1

Indications: Mild traumatic brain injury, Parkinson's disease

Partnerships

ATAI Life SciencesWeill Cornell Medical School

Beyond the preview

Go deeper on Neuronasal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronasal.

Explore the full profile